Shire: Too Big For Its Niches
Executive Summary
When UK specialty pharmaceutical company Shire Pharmaceuticals announced its $4 billion all-share acquisition of Canada's BioChem Pharma in December, the markets punished it with a 16% drop in share price. But Shire is getting too big to acquire merely niche product opportunities.
You may also be interested in...
MedPointe and Opportunities in Specialty Pharma: Speed is Expensive
The notion of building up a new drug company with the unwanted, undersized products of ever-bigger Big Pharma is hardly new. But MedPointe, with its acquisition of Carter Wallace's medical products business, is aiming to build up a new firm faster and bigger than can be done simply by in-licensing.
Bayer Places Consumer Cost Of Living Pressures 'Very High' On Agenda
Despite spiraling inflation, branded OTC product demand remains high, according to Bayer Consumer Health, which posted Q2 sales up by 16.0%. But with consumer incomes increasingly squeezed, the company is working on ways to defend its market share against cheaper private-label alternatives.
Over The Counter 8 Aug 2022: The ‘Dos and Don’ts’ Of EU Supplement Innovation, With Mihai Inceu
In this episode, HBW Insight talks to regulatory expert Mihai Inceu about the challenges of innovating in Europe’s thriving food supplements market. Senior regulatory affairs officer at consultancy firm Jensen R+, Inceu highlights some of the issues companies face in putting new wellness products onto the European market, particularly if they want to make health claims for herbal ingredients, also known as botanicals. As well as giving good advice about how to avoid getting into trouble with regulators, Inceu also points to some of the latest trends in this dynamic consumer health space.